FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

Share:

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma Transcript

Science

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma FDA medical oncologists discuss the agency’s March 23, 2017, approval of avelumab the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.